AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
NEWARK, Calif., Feb. 17, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2016 financial results after the close of market, Tuesday, February 21, 2017. The Company will host a conference call beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.
Participants can access the call by dialing (866) 643-3010 (United States) or (857) 270-6032 (International) referencing Conference ID 71033060. The conference call will also be available via a live webcast on the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
